Skip to main content

Web Exclusives

Second-Line Trastuzumab Deruxtecan in Patients with Metastatic Gastric or Esophageal Junction Cancer Demonstrates Clinical Efficacy
Gastrointestinal Cancers
Web Exclusives
Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response. Read More ›
The Importance of Recognizing Interstitial Lung Disease in the Clinical Setting, and the Impact of EGFR Tyrosine Kinase Inhibitors During the Pandemic
Lung Cancer
Web Exclusives
To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical. Read More ›
Treating Non–Small-Cell Lung Cancer with EGFR Mutations with Osimertinib as Adjuvant Therapy
Lung Cancer
Web Exclusives
Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial. Read More ›
First Study to Investigate Therapeutic Advantages of Managing Lung Cancer Through Telemedicine
Lung Cancer
Web Exclusives
Positive findings from this study support channeling additional resources into telemedicine care for lung cancer, and into future randomized controlled trials to verify effectiveness. Read More ›
Focusing on Lung Cancer Management and Palliative Care During the COVID-19 Pandemic
Lung Cancer
Web Exclusives
The COVID-19 pandemic has highlighted how critical it is to maintain resilience and flexibility of the healthcare system and healthcare providers. Read More ›
Treatment of EGFR Mutation–Positive Non–Small-Cell Lung Cancer with Tyrosine Kinase Inhibitors
Lung Cancer
Web Exclusives
Clinical data are highlighted, providing an understanding of the benefits of treatment with tyrosine kinase inhibitors. Read More ›
PARP Inhibitors Have Acceptable Toxicity Profiles and Have Shown Efficacy in Treatment of Ovarian Cancer
Women's Health
Web Exclusives
Emerging evidence suggests PARP inhibitors have the potential to revolutionize the treatment of ovarian cancer. Read More ›
Olaparib plus Bevacizumab Has Been Approved as Maintenance Therapy for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Women's Health
Web Exclusives
Patients with advanced ovarian cancer may be eligible to receive frontline maintenance treatment with olaparib plus bevacizumab. Read More ›
Coping Strategies Utilized by Women with Ovarian Cancer During the COVID-19 Pandemic
Women's Health
Web Exclusives
Ovarian cancer survivors frequently use adaptive and problem-focused coping strategies. During the COVID-19 pandemic, virtual technology has played a key role in shaping and determining these strategies. Read More ›
Alternatives to Intravenous Therapies for Ovarian Cancer During the COVID-19 Era
Women's Health
Web Exclusives
Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy. Read More ›

Page 9 of 26